Insulin Degludec And Liraglutide

Introduction Overview

Generic Name

insulin degludec and liraglutide

Brand Name

Xultophy

Dosage Form

Injection pen (autoinjector)

Drug Class

Antidiabetic combinations

Pharmacokinetics

Absorption:
Xultophy is a fixed-dose combination of insulin degludec, a long-acting insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Insulin degludec demonstrates a slow and steady absorption profile after subcutaneous injection, characterized by a delayed onset of action several hours post-injection and an ultra-long duration of activity exceeding 24 hours. This prolonged absorption is attributed to subcutaneous depot formation and multi-hexamer assembly in the injection site, facilitating gradual release into the circulation. Liraglutide is absorbed with a time to maximum concentration (Tmax) of approximately 8 to 12 hours after subcutaneous administration. The absorption of liraglutide is consistent and predictable, with an absolute bioavailability near 55%, largely independent of injection site.

Distribution:
After absorption, insulin degludec binds to insulin receptors in peripheral tissues, primarily muscle and adipose tissue. Its volume of distribution reflects its confinement to the extracellular compartment. Liraglutide is extensively bound (>98%) to plasma albumin, creating a reversible binding reservoir that prolongs its half-life and stabilizes plasma concentrations. The distribution of liraglutide is limited largely to plasma and interstitial fluids with minimal penetration to the central nervous system, which is relevant for its physiological effects on GLP-1 receptors located peripherally and in the brain.

Metabolism:
Insulin degludec is metabolized predominantly via enzymatic degradation by proteolytic enzymes forming amino acids and small peptides, without involvement of hepatic cytochrome P450 enzymes. Its metabolites are inactive. Liraglutide undergoes metabolism by proteolytic cleavage similar to endogenous GLP-1 peptides but is resistant to rapid degradation by dipeptidyl peptidase-4 (DPP-4) enzyme, attributed to its fatty acid side chain which also facilitates albumin binding. The metabolic fate results in small peptide fragments and amino acids that are subsequently eliminated.

Elimination:
The elimination half-life of insulin degludec is approximately 25 hours, enabling once-daily dosing with stable plasma levels and minimal peaks and troughs. Elimination occurs via the kidneys and liver by breakdown into amino acids and oligopeptides, with no significant renal excretion of intact insulin. Liraglutide has a half-life of approximately 13 hours, supporting once-daily administration. It is cleared via proteolytic catabolism with subsequent renal and hepatic elimination of metabolites. Due to these catabolic pathways, liraglutide dose adjustment is generally not required in mild to moderate hepatic or renal impairment, but caution is advised in severe cases. Both components have low potential for accumulation due to their degradation and elimination mechanisms.

The combined pharmacokinetic profile of Xultophy provides continuous basal insulin delivery paired with GLP-1 receptor agonist activity, optimizing glycemic control with reduced variability and a convenient once-daily injection regimen.

Dosage Forms

Available Dosage Forms:
- Xultophy is supplied as a prefilled, disposable autoinjector pen containing 3 mL of solution.
- Each mL contains insulin degludec 100 units and liraglutide 3.6 mg (equivalent to 100 units of insulin degludec and 3.6 mg liraglutide per mL).
- The total amount per pen is 300 units of insulin degludec and 10.8 mg of liraglutide.

Dosages for Adults and Adolescents:
- Initial dosing for adults naive to basal insulin or GLP-1 receptor agonists starts at 10 units subcutaneously once daily.
- For those currently receiving basal insulin and/or liraglutide, initial dose is 16 units once daily, discontinuing previous therapies accordingly.
- Dose titration is individualized, increasing or decreasing by 2 units every 3 to 4 days based on fasting plasma glucose and glycemic goals.
- Maximum daily dose is 50 units insulin degludec and 1.8 mg liraglutide (equivalent unit dose on the pen scale).
- The dosing scale on the pen represents the insulin units, with an associated liraglutide dose displayed via a dosing table.

Specific Patient Populations:
- Not approved for pediatric use under 18 years of age.
- Use with caution in patients with hepatic or renal impairment; dosage adjustments may be needed based on clinical response.
- Not recommended as first-line therapy due to uncertainty regarding rodent thyroid C-cell tumor findings.
- Not studied in combination with prandial insulin; concomitant mealtime insulin requires clinical monitoring.

Clinical guidelines emphasize individualized dose titration guided by regular blood glucose monitoring, especially during periods of illness, changes in physical activity, or dietary habits.

Mechanism Of Action

Xultophy combines two pharmacologically distinct agents—insulin degludec and liraglutide—to achieve complementary mechanisms that improve glycemic control in type 2 diabetes mellitus.

Insulin degludec is an ultra-long-acting basal insulin analog designed to mimic endogenous basal insulin secretion. Upon subcutaneous injection, insulin degludec forms multi-hexamers that slowly dissociate into monomers, resulting in a protracted absorption profile and stable plasma insulin levels over 24 hours and beyond. Insulin binds to insulin receptors on muscle and adipose tissues, activating the receptor’s tyrosine kinase activity, leading to downstream phosphorylation events that facilitate glucose uptake by GLUT4 translocation, glycogen synthesis stimulation, inhibition of gluconeogenesis, and lipid synthesis modulation. This receptor-mediated signaling cascade effectively lowers blood glucose by enhancing peripheral utilization and suppressing hepatic glucose output.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1. It activates the GLP-1 receptor, a G-protein coupled receptor found on pancreatic beta cells, enhancing glucose-dependent insulin secretion. Liraglutide also suppresses glucagon secretion from alpha cells during hyperglycemia, slows gastric emptying, and promotes satiety via central nervous system pathways. These actions result in reduced postprandial glucose excursions, decreased appetite, and improved beta-cell function. The fatty acid side chain on liraglutide confers albumin binding and resistance to dipeptidyl peptidase-4 (DPP-4) degradation, prolonging its half-life.

The combination of insulin degludec with liraglutide in Xultophy allows for basal insulin coverage while leveraging the glucose-dependent insulinotropic and glucagonostatic effects of liraglutide, achieving enhanced glycemic control through multiple complementary mechanisms. Clinical studies demonstrate that this co-formulation improves fasting and postprandial glucose levels with lower risk of hypoglycemia and potential weight loss benefits compared with basal insulin alone.

Compared to other basal insulin and GLP-1 receptor agonist combinations, Xultophy uniquely combines insulin degludec and liraglutide, offering ultra-long basal insulin duration combined with a high-potency GLP-1 analog, leading to sustained glucose control and tolerability. Research evidence supports improved HbA1c reductions and reduced hypoglycemia with Xultophy versus basal insulin or liraglutide monotherapies, establishing its clinical utility in type 2 diabetes management.

Pharmacological Actions

Basal insulin replacement via insulin degludec's prolonged activity mimicking endogenous insulin secretion.
Enhancement of glucose-dependent insulin secretion through liraglutide-mediated GLP-1 receptor activation.
Suppression of inappropriate glucagon secretion during hyperglycemia by liraglutide.
Slowing of gastric emptying to reduce postprandial glucose excursions.
Promotion of satiety and potential reduction in food intake via central nervous system pathways influenced by liraglutide.
Improvement of beta-cell function and insulin sensitivity due to combined insulin and GLP-1 effects.
Reduction of fasting and postprandial blood glucose concentrations.
Potential weight loss mediated by liraglutide-induced appetite suppression.
Lower risk of hypoglycemia compared to basal insulin alone due to glucose-dependent action of liraglutide.
Stabilization of plasma glucose levels with reduced glycemic variability.
Combination of two synergistic mechanisms addressing multiple pathophysiological defects of type 2 diabetes.
Pharmacodynamic complementarity minimizing insulin dose requirements.
Extended duration of action enabling once-daily dosing and improved patient adherence.
Albumin binding of liraglutide prolonging its half-life and stabilizing plasma concentrations.
Proteolytic metabolism minimizing drug-drug interactions.

Therapeutic Or Clinical Uses

Indicated as adjunct therapy to diet and exercise in adults with type 2 diabetes mellitus to improve glycemic control.
Used when blood glucose levels are inadequately controlled by basal insulin or GLP-1 receptor agonists alone.
Alternative to basal insulin with potential additional benefits of weight reduction.
Treatment option for patients seeking to minimize hypoglycemia risk while achieving HbA1c targets.
Not intended for use in type 1 diabetes mellitus or diabetic ketoacidosis.
Useful in patients with insulin resistance requiring combined basal insulin and incretin therapy.
Preferred in clinical scenarios where persistent hyperglycemia is present despite oral hypoglycemics and lifestyle changes.
Option for patients who have failed monotherapy with GLP-1 receptor agonists or basal insulin.
Can be part of a comprehensive glucose-lowering regimen targeting fasting and postprandial hyperglycemia.
Provides a simplified regimen through fixed-ratio combination, improving adherence.
May confer cardiovascular benefits through liraglutide's GLP-1 mediated effects.
Helps reduce glycemic variability, potentially improving long-term diabetes complications outcomes.
Indicated for adult patients due to lack of safety data in pediatric populations.
Not recommended as first-line therapy due to caution from rodent studies related to thyroid C-cell tumors.
Utilized under specialist supervision with glucose monitoring and dose titration.

Side Or Adverse Effects

Nausea, often mild to moderate, typically transient during initial treatment phase.
Diarrhea and gastrointestinal disturbances including vomiting and abdominal discomfort.
Headache, potentially related to glycemic control changes.
Upper respiratory tract symptoms such as stuffy or runny nose, sneezing, and sore throat.
Injection site reactions including pain, redness, or irritation.
Risk of hypoglycemia, especially if used concomitantly with other insulin secretagogues or insulin.
Pancreatitis, characterized by severe persistent abdominal pain radiating to the back with nausea and vomiting.
Signs of allergic reactions including rash, hives, difficulty breathing, and swelling of face, lips, tongue, or throat.
Potential thyroid C-cell tumors observed in animal studies; thyroid neoplasms yet unconfirmed in humans.
Edema and weight gain have been reported less commonly.
Kidney impairment signs such as reduced urination, painful urination, or rapid weight gain.
Electrolyte imbalances including low potassium levels presenting as leg cramps, irregular heartbeats, and muscle weakness.
Gastrointestinal adverse effects may lead to dehydration requiring clinical monitoring.
Rare hypersensitivity reactions including anaphylaxis.
Potential for increased heart rate due to liraglutide's pharmacologic activity.

Precautions

Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Use with caution in patients with a history of pancreatitis; monitor for pancreatic symptoms.
Careful dose titration necessary to minimize hypoglycemia risk, especially during changes in diet, exercise, or illness.
Monitor renal function in patients with pre-existing kidney impairment or dehydration risk.
Avoid use during episodes of hypoglycemia or diabetic ketoacidosis.
Not recommended for type 1 diabetes or patients requiring prandial insulin without specialist advice.
Avoid injection into areas of skin that are bruised, thickened, or scarred to prevent inconsistent absorption.
Use cautiously in patients with gastrointestinal motility disorders due to liraglutide's effect on gastric emptying.
Discontinue prior basal insulin or GLP-1 receptor agonists before initiating Xultophy as per clinical judgment.
Pregnancy: Use only if clearly needed; control of diabetes is crucial during pregnancy but safety data is limited.
Breastfeeding: Exercise caution; potential excretion in human milk unknown.
Patients with a history of alcohol abuse require close monitoring due to altered glycemic control sensitivity.
Avoid alcohol intake which may potentiate hypoglycemia and impair glucose control.
Replacement or dose adjustment may be necessary in acute illness, surgical procedures, or severe stress.
Educate patients on recognizing and managing hypoglycemia symptoms and emergency glucagon use.

Warnings

Risk of medullary thyroid carcinoma based on rodent studies; human relevance unknown but serious precaution advised.
Contraindicated in multiple endocrine neoplasia type 2 syndrome and in patients with a personal or family history of medullary thyroid carcinoma.
Not to be used in insulin-dependent diabetes mellitus or diabetic ketoacidosis.
Use caution or avoid in patients with severe gastrointestinal disease affecting motility or absorption.
Hypoglycemia risk especially when combined with sulfonylureas or other insulin secretagogues.
Potential for acute pancreatitis; discontinue if pancreatitis symptoms occur.
Monitor for signs of thyroid tumors such as neck swelling, dysphagia, hoarseness, and respiratory difficulty.
Avoid sharing injection pens to prevent transmission of infections.
Do not use if the solution appears cloudy, discolored, or contains particles.
Store pens properly; freezing or heat exposure can degrade insulin activity.
Use only the dedicated injection pen supplied; do not mix or dilute with other medications.
Severe hypersensitivity or allergic reactions have been reported; seek emergency care if symptoms develop.
Avoid abrupt discontinuation of therapy; glycemic destabilization may occur.
Limit maximum daily dose to 50 units to prevent overdose and hypoglycemia.
Patients should be educated to adjust doses carefully during physiological changes and stress conditions.

Contraindication

Known hypersensitivity to insulin degludec, liraglutide, or any component of the formulation.
Personal or family history of medullary thyroid carcinoma.
Multiple endocrine neoplasia syndrome type 2.
Type 1 diabetes mellitus.
Diabetic ketoacidosis, which requires insulin therapy and correction of underlying metabolic abnormalities separately.
Patients receiving other GLP-1 receptor agonists concomitantly (e.g., dulaglutide, exenatide, lixisenatide).
Patients experiencing episodes of hypoglycemia at the time of intended injection.
Use during episodes of severe gastrointestinal disease or gastroparesis may be contraindicated.
Known severe hypersensitivity or anaphylactic reactions to previous insulin or GLP-1 therapies.
Not indicated or studied in pediatric patients under 18 years of age.
Pregnancy and breastfeeding not explicitly contraindicated but use only if benefits outweigh risks as per healthcare provider.
Do not use product if solution is cloudy, discolored, or contains particulate matter.
Patients with severe hepatic or renal impairment not advised without specialist monitoring.
Concomitant use with prandial insulin has not been studied and is generally contraindicated.
Patients unable to adhere to dosing or storage recommendations.

Drug Interactions

Concomitant use with other GLP-1 receptor agonists may increase risk of adverse effects and is contraindicated.
Sulfonylureas and other insulin secretagogues increase risk of hypoglycemia when used with Xultophy.
Thiazolidinediones may cause fluid retention and exacerbate heart failure risk when combined with insulin.
Beta-blockers, clonidine, and reserpine may mask hypoglycemia symptoms, complicating clinical management.
Alcohol consumption can potentiate hypoglycemia and unpredictable blood glucose changes.
Corticosteroids and sympathomimetics may antagonize insulin effects, leading to hyperglycemia.
Diuretics like thiazides can impair glucose tolerance and increase insulin requirements.
Medications that slow gastrointestinal motility may enhance liraglutide absorption and effects.
Co-administration with prandial insulin has not been studied; caution needed.
Drugs affecting renal function can alter insulin pharmacodynamics due to reduced clearance.
Medications inducing or inhibiting cytochrome P450 enzymes have limited interaction as both components are catabolized proteolytically.
Use caution with ACE inhibitors and angiotensin receptor blockers due to potential hyperkalemia risk.
Interference with other injectable agents at the same site can affect absorption; avoid mixing injections.
Patients on multiple antihypertensives should be monitored closely as blood pressure may be affected.
Consult healthcare providers before starting any new medications including over-the-counter and herbal supplements.

Preparations Of The Drug

Xultophy 100/3.6 is available as a prefilled disposable injection pen (autoinjector).
Each pen contains 3 mL solution with insulin degludec at 100 units/mL and liraglutide at 3.6 mg/mL.
Strength per pen: 300 units insulin degludec and 10.8 mg liraglutide total.
The solution is clear, colorless, and free from visible particles.
The product is supplied with pen needles compatible with the autoinjector.
Prefilled pen allows dosing in units of insulin degludec; liraglutide dose corresponds to insulin units (0.036 mg per unit).
Storage requires refrigeration of unopened pens (2°C to 8°C); do not freeze.
Opened pens can be kept at room temperature and used within 21 days, protected from heat and light.
Do not store pens with needles attached to prevent contamination and leakage.
Phenol is used as a preservative in the formulation to maintain sterility.
Contains inactive ingredients such as glycerol, zinc chloride, and water for injection.
Pens provide accurate dose increments of 1 unit insulin degludec equivalent.
Not intended for mixing with other insulins or medications.
Disposal of used pens must follow local regulations for biomedical waste.
Prescribing information available outlining detailed handling, administration, and dosing instructions.